Structure Based Multitargeted Molecular Docking Analysis of Selected Furanocoumarins against Breast Cancer

Author:

Acharya Reetuparna,Chacko Shinu,Bose Pritha,Lapenna Antonio,Pattanayak Shakti Prasad

Abstract

Abstract Breast cancer is one of the biggest global dilemmas and its current therapy is to target the hormone receptors by the use of partial agonists/antagonists. Potent drugs for breast cancer treatment are Tamoxifen, Trastuzumab, Paclitaxel, etc. which show adverse effects and resistance in patients. The aim of the study has been on certain phytochemicals which has potent actions on ERα, PR, EGFR and mTOR inhibition. The current study is performed by the use of molecular docking as protein-ligand interactions play a vital role in drug design. The 3D structures of ERα, PR, EGFR and mTOR were obtained from the protein data bank and docked with 23 3D PubChem structures of furanocoumarin compounds using FlexX. Drug-likeness property was checked by applying the Lipinski’s rule of five on the furanocoumarins to evaluate anti-breast cancer activity. Antagonist and inhibition assay of ERα, EGFR and mTOR respectively has been performed using appropriate in-vitro techniques. The results confirm that Xanthotoxol has the best docking score for breast cancer followed by Bergapten, Angelicin, Psoralen and Isoimperatorin. Further, the in-vitro results also validate the molecular docking analysis. This study suggests that the selected furanocoumarins can be further investigated and evaluated for breast cancer treatment and management strategies.

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Reference36 articles.

1. Donepudi, M. S., Kondapalli, K., Amos, S. J. & Venkanteshan, P. Breast cancer statistics and markers. Journal of Cancer Research and Therapeutics 10, 506–511 (2014).

2. Akram, M., Iqbal, M., Daniyal, M. & Khan, A. U. Awareness and current knowledge of breast cancer. Biological Research 15, 1–23 (2017).

3. Kuhl, H. & Schneider, H. P. G. Progesterone – promoter or inhibitor of breast cancer. Climacteric 16, 54–68 (2013).

4. Blamey, R. et al. Hormones and breast cancer. Human Reproduction Update 10, 281–293 (2004).

5. Wang, Z. Y. & Yin, L. Estrogen receptor alpha-36 (ER-α36): a new player in human breast cancer. Molecular and cellular endocrinology 15, 1–34 (2015).

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3